ArriVent BioPharma, Inc. AVBP
Updated: 18 Jun 2026
No signal published yet
We already track ArriVent BioPharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow ArriVent BioPharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ArriVent BioPharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 11, 2026, ArriVent reported Q1 2026 financial results, highlighting a cash position of $326.4 million and progress in its pivotal Phase 3 FURVENT study. The company also announced IND clearance for ARR-002, a novel antibody-drug conjugate, with plans to begin patient dosing in the second half of 2026.
What Firelda Watch includes for ArriVent BioPharma, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow ArriVent BioPharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ArriVent BioPharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more